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DNase1 has been implicated in a number of immune disorders and is an excellent candidate gene for Crohn’s disease (CD).
We investigated whether DNase1 SNPs rs1053874 and rs8176938 were associated with CD in a well-characterized New Zealand
dataset consisting of 447 cases and 716 controls. Furthermore, we measured serum DNase1 activity levels in a number of CD
patients and controls. We did not ﬁnd any evidence of association for either DNase1 genetic variation or DNase1 activity levels
with CD. The lack of association indicates that DNase1 does not play a signiﬁcant role in predisposing to CD in the New Zealand
population.
1.Introduction
Deoxyribonuclease 1 (DNase1) is an endonuclease that
facilitates chromatin breakdown. Deﬁciency in DNase1 and
the resulting diﬃculty of removing DNA from nuclear
antigens promote susceptibility to immune disorders such as
systemic lupus erythematosus (SLE) [1, 2], Sjogren’s disease
[3], and thyroid autoimmunity [4] .Ar e c e n tr e p o r th a sa l s o
provided some evidence for a role in Crohn’s disease (CD)
[5].
Genetic variation in DNase1 has been associated with
SLE [6]. Studies of associations between DNase1 genetic
variants and CD have not been reported to date.
We investigated whether DNase1 SNPs rs1053874 and
rs8176938 were associated with CD in a well-characterized
case-control New Zealand dataset. Furthermore, we mea-
sured serum DNase1 activity levels in a number of CD
patients and controls.
2. Methods
2.1. Samples. A total of 1163 subjects from New Zealand
were included in the study: 447 cases and 716 controls. All
participants self-reported European ancestry.
Clinical records were analysed to conﬁrm diagnosis, and
IBD status was deﬁned using standard diagnostic criteria
[7]. Cases were phenotyped according to the Montreal
classiﬁcation systems.
Participants consented to collection of peripheral blood
or a buccal swab for DNA extraction and genotyping, and
DNA was extracted from the blood/buccal samples using
Qiagen’s DNA extraction kit and following the manufac-
turer’s instructions.
The study was conducted under ethical protocol
MEC/04/12/011, authorised through the New Zealand Mul-
tiregion Human Ethics Committee. All study subjects gave
informed consent.2 ISRN Gastroenterology
Table 1: Genotype and allele counts (and frequencies) in CD patients and in controls.
SNP Case Control P Case Control P
rs1053874
A/A 40 (9.0) 65 (9.2) 0.56 A 262 (29.5) 442 (31.2) 0.40
A/G 182 (41.0) 312 (44.0) G 626 (70.5) 976 (68.8)
G/G 222 (50.0) 332 (46.8)
rs8176938
C/C 410 (91.7) 644 (91.2) 0.83 C 855 (95.6) 1348
(95.5) 0.85
C/G 35 (7.8) 60 (8.5) G 39 (4.4) 64 (4.5)
G/G 2 (0.4) 2 (0.3)
Table 2: Relationships between SNPs and subphenotypes.
rs1053874 (tested allele: G) rs8176938 (tested allele: C)
OR (95% CI) P OR (95% CI) P
Age at diagnosis
<17 0.86 (0.54–1.36) 0.509 1.45 (0.45–4.60) 0.533
17 to 40 1.02 (0.81–1.28) 0.900 1.36 (0.80–2.33) 0.259
40< 1.08 (0.72–1.62) 0.707 0.86 (0.39–1.89) 0.712
CD behaviour
inﬂammatory 1.12 (0.88–1.44) 0.361 1.27 (0.72–2.22) 0.411
stricturing 0.78 (0.58–1.06) 0.113 1.01 (0.53–1.95) 0.969
penetrating 1.22 (0.74–2.00) 0.433 2.20 (0.53–9.10) 0.275
CD location
Ileal 0.96 (0.72–1.29) 0.802 0.86 (0.49–1.52) 0.605
Colonic 1.11 (0.82–1.51) 0.500 1.62 (0.74–3.54) 0.229
Ileocolonic 0.95 (0.69–1.30) 0.726 1.75 (0.75–4.10) 0.195
Other IBD family Y 0.89 (0.54–1.48) 0.651 1.20 (0.37–3.89) 0.759
Bowel resection Y 0.91 (0.68–1.21) 0.517 1.43 (0.70–2.91) 0.322
EIM Y 0.89 (0.61–1.32) 0.568 0.90 (0.41–1.98) 0.799
Perianal disease Y 1.33 (0.84–2.10) 0.226 —
Severity Y 1.00 (0.69–1.47) 0.982 1.19 (0.51–2.78) 0.695
Smoking Y 1.08 (0.74–1.58) 0.677 0.95 (0.34–2.61) 0.916
Table 3: DNase1 activity by subphenotype.
Estimate (95% CI) P
Age at diagnosis
<17 −0.23 (−4.09–3.64) 0.908
17 to 40 1.51 (−0.75–3.78) 0.190
40< −2.37 (−6.39–1.65) 0.247
CD behaviour
inﬂammatory −0.16 (−2.66–2.35) 0.903
stricturing 1.96 (−1.01–4.93) 0.195
penetrating 0.88 (−3.32–5.07) 0.681
CD location
Ileal 0.10 (−2.76–2.97) 0.943
Colonic 1.29 (−1.61–4.19) 0.382
Ileocolonic 0.38 (−2.69–3.44) 0.809
Other IBD family Y 0.50 (−4.56–5.57) 0.846
Bowel resection Y 1.38 (−1.47–4.23) 0.340
EIM Y −0.14 (−3.63–3.35) 0.939
Perianal disease Y −0.83 (−4.79–3.14) 0.681
severity Y 1.05 (−2.48–4.59) 0.559
Smoking Y 1.01 (−3.46–5.65) 0.633ISRN Gastroenterology 3
2.2. Genotyping. We searched for SNPs in the DNase1 gene
in the hapmap database and identiﬁed 2 common (MAF >
5%) SNPs: rs1053874 and rs8176938. We genotyped these
SNPs using the ABI TaqMan MGB diallelic discrimination
system and predesigned assays on demand (Applied Biosys-
tems, Melbourne, Australia). The polymerase chain reaction
ampliﬁcation was performed using the ABI Prism 7900 HT
sequence-detector machine using the following conditions:
10 minutes at 95◦C, followed by 40 cycles at 92◦Cf o r1 5
seconds and 60◦C for 1 minute. The allelic discrimination
results were determined after the ampliﬁcation by perform-
ing an endpoint read.
All sample plates contained cases, controls, blanks,
hapmap, and duplicate samples. Quality control measures
included independent double genotyping, blind to sample
identity, and comparison of our hapmap sample genotypes
to those in the hapmap database (http://www.hapmap.org/).
2.3. Measurement of DNase1 Activity Levels. DNase1 activity
levels were measured in the serum of 213 CD patients
and 209 controls using a commercially available validated
enzyme-linked immunosorbent assay(ELISA)kit(Orgentec,
Germany), and the protocol was followed as described by
the manufacturer. All samples were analyzed in duplicate.
Activity levels were determined from a standard curve using
a 4-parameter-ﬁt with lin-log coordinates for optical density
and concentration.
2.4. Statistical Analysis. SNPs were tested for deviation
from HWE in both cases and controls using a chi-square
goodness-of-ﬁt test. To determine if there were diﬀerences
between cases and controls, genotype and allele frequencies
for each SNP were analyzed by 2 × 3a n d2× 2 Chi-square
tables, respectively.
Genotype and phenotype associations were assessed by
comparing allele frequencies between controls and patient
subgroups deﬁned using the clinical characteristics. These
analyses were carried out using R (R: a language and
environment for statistical computing, R Foundation for
Statistical Computing, Vienna, Austria. ISBN 3-900051-
07-0, URL http://www.r-project.org/) and SAS (V9.1 SAS
Institute., Cary, NC, USA).
Across-group comparisons of serum DNase 1 activity
were tested using a generalized linear model for mean
diﬀerences.
3. Results
3.1. Comparison of DNase1 Genotypes in CD Patients and
Healthy Controls. Both SNPs were in Hardy-Weinberg
equilibrium. Neither was found to be associated with CD
(Table 1). We undertook a phenotype analysis, and there
were no associations with any of the diﬀerent clinical
characteristics of CD (Table 2).
3.2. Comparison of DNase1 Activity Levels in CD Patients and
Healthy Controls. DNase1 activity levels were measured in
the serum. Activity in the controls ranged from 43 to 100%.
Activity in the cases ranged from 39 to 100%. The mean
serum DNase1 activity for CD patients was 80% and that for
the controls was also 80%. Thus, there was no diﬀerence in
activity levels between cases and controls. We also compared
DNase1 activity levels across the diﬀerent CD phenotypes,
buttherewerenosigniﬁcantﬁndings(Table 3).Neitherthere
were any diﬀerences when comparing by gender.
4. Discussion
DNase1 is known to be involved in a number of immune
disorders, but research into its role in CD has been rare.
There have been no previous studies investigating associa-
tions between genetic variation in DNase1 and CD, and only
one published study examined DNase1 activity levels in CD.
We were unable to replicate the association reported in
previous research in which DNase1 activity in CD patients
was signiﬁcantly lower than in healthy individuals [5]. In our
study there was no diﬀerence in the DNase1 activity levels.
All of the CD patients in the previous study had active severe
disease. Our sample set was larger and contained a range of
diﬀerent phenotypes but when we stratify by these diﬀerent
phenotypes, including severity, we were still unable to
see any associations with DNase1. Nonreproducibility does
not necessarily demonstrate that the original association
reported was spurious and should not discourage further
research in this promising ﬁeld. True associations may not
replicate across diﬀerent data sets for a number of reasons.
As well as investigating DNase1 activity levels, we also
undertook an analysis of genetic variation in DNase1 and
compared the genotype and allele frequencies of 2 SNPs
in CD patients and controls. Genetic variation in DNase1
has previously been associated with SLE [6] but in the
s t u d yw er e p o r th e r ew ew e r en o ta b l et oﬁ n da n ye v i d e n c e
for association between DNase1 SNPs and CD. Data from
a recent CD genomewide meta-analysis [8] also does not
provide support for DNase1 being associated with CD:
SNP rs1053874 was included in the analysis, and the allele
frequencies did not diﬀer between cases and controls.
To summarise, although DNase1 is a good candidate for
CD, in the present study we failed to detect any signiﬁcant
associations.TheabsenceofassociationbetweenDNase1and
CD indicates that DNase1 does not play a signiﬁcant role in
predisposing to CD in the New Zealand population.
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